Καλώς ήρθατε στην διαδικτυακή μας κοινότητα.
Εδώ μπορείτε να συζητήσετε και να ενημερωθείτε για θέματα που αφορούν την Πρωτοβάθμια Φροντίδα Υγείας.
Για να συμμετέχετε και να μπορείτε να κατεβάσετε αρχεία και εικόνες που βρίσκονται στα μηνύματα πρέπει να εγγραφείτε.
Η εγγραφή είναι δωρεάν και θα σας αποσταλεί άμεσα ένα e-mail για την ενεργοποίηση της εγγραφής σας.
Εάν δεν το λάβετε σε λίγα λεπτά ελέγξετε το φάκελο ομαδικής αλληλογραφίας ή το φάκελο SPAM ή το φάκελο ανεπιθύμητης αλληλογραφίας καθώς μπορεί να βρεθεί εκεί από λάθος του λογισμικού ηλεκτρονικού ταχυδρομείου.
Εάν έχετε ξεχάσει τον κωδικό σας, μπορείτε να ζητήσετε να σας ξανασταλεί από εδώ.
7 Νοεμβρίου 2024, 23:48:04

Αποστολέας Θέμα: Europe Fines Servier in Pay-for-Delay Crackdown  (Αναγνώστηκε 5144 φορές)

0 μέλη και 1 επισκέπτης διαβάζουν αυτό το θέμα.

10 Ιουλίου 2014, 14:14:14
Αναγνώστηκε 5144 φορές
Αποσυνδεδεμένος

Denominator

Moderator
Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος


Europe Fines Servier in Pay-for-Delay Crackdown

BRUSSELS — Fines totaling 427.7 million euros ($581.8 million) were imposed Wednesday on several European drug makers, including the French company Servier, for keeping more affordable forms of a popular heart treatment off the market.

The case is part of a broader crackdown in Europe against drug makers that pay to delay the introduction of generic versions of their medications after some of their patent protections expire. Regulators in the United States are also clamping down.

Servier, which was fined €331 million ($450 million), condemned aspects of the decision by Europe’s top antitrust enforcer as “absurd,” and said it would be “detrimental to patients” because it would limit its research efforts. The company, based in Suresnes, near Paris, said it would appeal the decision to the General Court, the second-highest tribunal in the European Union.

The case against Servier focused on how it protected its blood pressure medicine, perindopril.

“Servier had a strategy to systematically buy out any competitive threats to make sure that they stayed out of the market,” Joaquín Almunia, the European Union’s commissioner for competition policy, said at a news conference in Brussels. Such “behavior is clearly anticompetitive and abusive” and such “practices directly harm patients, national health systems and taxpayers,” Mr. Almunia said.

Servier’s tactics included buying the rights to an alternative process for manufacturing a version of perindopril, preventing makers of generics from bringing a competing product to market, according to European Union officials. The makers of generics then challenged some of Servier’s secondary patents in court, but Servier effectively bought them off with settlements, including significant cash payments, the officials said.

One generics company, which was not named, acknowledged that it was “bought out of perindopril.” Another producer said it agreed to market generic perindopril in just seven national markets in Europe, according to the evidence.

In a case in Britain, where the patent on the perindopril molecule expired in 2003, Servier blocked the introduction of a generic version for four years. Prices dropped by an average of 90 percent once the generic version was allowed onto the British market in 2007, the officials said.

The commission did not name the companies in the evidence it presented. But fines totaling €96.7 million were levied against five producers of generics: Unichem Laboratories, based in India, and a subsidiary, Niche Generics; Matrix, now part of Mylan of Pennsylvania; Teva Pharmaceutical, based in Israel; Krka, based in Slovenia; and Lupin, also based in India.

In a statement, Teva said, “We stand by our belief that Teva did not engage into any anticompetitive behavior.” It said it had not yet decided whether to appeal against its fine of €15.6 million.

The push to rid the industry of such pay-for-delay deals could give patients better access to less costly medicines at a time when patents worth tens of billions of euros have been expiring.
Μελλοθάνατε ιατρέ, οι ασθενείς σου σε χαιρετούν.

Λέξεις κλειδιά: pay-for-delay γενοσημα coversyl 
 

Σχετικά θέματα

  Τίτλος / Ξεκίνησε από Απαντήσεις Τελευταίο μήνυμα
0 Απαντήσεις
2484 Εμφανίσεις
Τελευταίο μήνυμα 19 Ιουνίου 2009, 13:03:06
από Raptor
0 Απαντήσεις
2221 Εμφανίσεις
Τελευταίο μήνυμα 3 Σεπτεμβρίου 2011, 10:02:21
από KERASIDISN
0 Απαντήσεις
3547 Εμφανίσεις
Τελευταίο μήνυμα 5 Σεπτεμβρίου 2011, 23:11:16
από Argirios Argiriou
0 Απαντήσεις
7888 Εμφανίσεις
Τελευταίο μήνυμα 10 Δεκεμβρίου 2019, 08:46:58
από Argirios Argiriou
0 Απαντήσεις
14648 Εμφανίσεις
Τελευταίο μήνυμα 24 Νοεμβρίου 2022, 21:22:46
από Argirios Argiriou